biome

(redirected from BIOM)
Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia.
Related to BIOM: BOM

biome

 [bi´ōm]
a large, distinct, easily differentiated community of organisms arising as a result of complex interactions of climatic factors, flora, fauna, and substrate; usually designated according to kind of vegetation present, such as tundra, coniferous forest, deciduous forest, or grassland.

bi·ome

(bī'ōm),
The total complex of biotic communities occupying and characterizing a particular geographic area or zone.
[bio- + -ome]

biome

(bī′ōm′)
n.
A major regional or global biotic community, such as a grassland or desert, characterized chiefly by the dominant forms of plant life and the prevailing climate.

biome

[bī′ōm]
Etymology: Gk, bios + oma, tumor, mass
the collection of biological communities existing in and characteristic of a broad geographic region, such as desert, tropical forest, or savanna. A biome includes all organisms of a particular region.

biome

An ecosystem with a distinct climate, organisms and substrates, all of which interact to produce a distinct and complex biotic community.

bi·ome

(bī'ōm)
The total complex of biotic communities occupying and characterizing a particular geographic area or zone.

biome

a major regional ecological community of organisms usually defined by the botanical habitat in which they occur and determined by the interaction of the substrate, climate, fauna and flora. The term is often limited to denote terrestrial habitats, e.g. tundra, coniferous forest, grassland. Oceans may be considered as a single biome (the marine biome), though sometimes this is subdivided, e.g. coral reef biome. There is no sharp distinction between adjacent biomes.

biome

a large, distinct, easily differentiated community of organisms in a major ecological region.
References in periodicals archive ?
BioMS Medical is a Canadian-based biotechnology company.
BioMS is conducting ongoing pivotal clinical trials evaluating the ability of dirucotide to affect disease progression in patients with secondary progressive MS:
The proposed mechanism of action, according to BioMS Medical, is to reintroduce "a state of 'tolerance' to a critical portion of the nerve's myelin basic protein that is an immunological site of attack in many MS patients.
BioMS Medical Corp (TSX: MS), Edmonton, Canada, a leading developer of products for the treatment of multiple sclerosis (MS), has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS.
Following the announcement of these disappointing results, Lilly and BioMS announced that they will be discontinuing other studies which were being conducted with dirucotide.
Active Biotech Acorda Therapeutics Aegera Idera Allergan Antisense Therapeutics Apitope Argyll Biotechnologies Asphelia Bayer-Schering Bayhill Therapeutics Berlex Laboratories Biogen Idec BioMS BioPartners BTG Elan Pharmaceuticals Eli Lilly Fornix GemacBio Genentech GlaxoSmithKline GW Pharmaceuticals IMS Indevus InterMune Isis Manhattan Medarex MediciNova Merck KGaA Merck Serono Millennium Mitsubishi Tanabe Pharma Momenta Pharmaceuticals Mylan Natco Pharmaceuticals Neuren Novartis Opexa Orchestra Therapeutics Otsuka Pharmaceuticals PDL BioPharma Pfizer ReceptoPharm Rentschler Roche Sanofi-Aventis Teva Transition UCB